<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796263</url>
  </required_header>
  <id_info>
    <org_study_id>HAART for Acute HIV infection</org_study_id>
    <nct_id>NCT00796263</nct_id>
  </id_info>
  <brief_title>Antiretroviral Therapy for Acute HIV Infection</brief_title>
  <acronym>AAHIV</acronym>
  <official_title>Antiretroviral Therapy for Acute HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South East Asia Research Collaboration with Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thai Red Cross AIDS Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>South East Asia Research Collaboration with Hawaii</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a protocol designed to randomize subjects with acute HIV infection to receive
      standard HAART or mega-HAART for subject who are enrolled in SEARCH 010 study (protocol
      title: Establish and characterize an acute HIV infection cohort in a Thai high risk
      population.

      To describe the impact of standard HAART versus mega-HAART initiated during the acute HIV
      infection period on immunological and virological outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-1 plasma viral RNA measurements and CD4 counts during follow-up and after therapy

      Number of HIV and non-HIV related clinical events Adverse events related to HAART Adherence
      to HAART Resistance to antiretroviral medications
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-1 plasma viral RNA measurements and CD4 counts during follow-up and after therapy</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of HIV and non-HIV related clinical events</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to HAART</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to HAART</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistance to antiretroviral medications</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">536</enrollment>
  <condition>Acute HIV Infection</condition>
  <arm_group>
    <arm_group_label>HAART</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The proposed HAART regimen consists of:
2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications
Dolutegravir(DTG) 50 mg orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mega-HAART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The proposed mega-HAART regimen consists of:
2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications
Dolutegravir(DTG) 50 mg orally once daily
Maraviroc (MVC)300 mg orally twice daily (for a period not exceeding the first24 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAART</intervention_name>
    <description>2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily
Dolutegravir(DTG) 50 mg orally once daily</description>
    <arm_group_label>HAART</arm_group_label>
    <other_name>Kivexa</other_name>
    <other_name>Tivicay</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mega-HAART</intervention_name>
    <description>2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily
Dolutegravir(DTG) 50 mg orally once daily
Maraviroc (MVC) 600 mg orally twice daily</description>
    <arm_group_label>Mega-HAART</arm_group_label>
    <other_name>Kivexa</other_name>
    <other_name>Tivicay</other_name>
    <other_name>Celsentri</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 18 years old

          2. Enrolled in SEARCH 010 protocol and have protocol-defined acute HIV-1 infection
             (Tested 4th generation HIV EIA negative and NAT positive or tested 4th generation HIV
             EIA positive, negative by less sensitive EIA and NAT positive)

          3. Choose to start HAART according to protocol

          4. Understand the study and sign informed consent form. Persons who cannot read will have
             the consent form read to them by a study staff and they can give informed consent by
             using thumb print.

          5. Availability for follow-up for the planned study duration

        Exclusion Criteria:

        1. Persons who have a history of a medical or psychiatric disorder by investigator's
        interview and physical examination according to standard practices, that in the judgment of
        the investigator(s), would interfere with or serve as a contraindication to adherence to
        the study protocol or ability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Praphan Phanuphak, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thai Red Cross AIDS Research Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Praphan Phanuphak, M.D., Ph.D</last_name>
    <phone>66 2 253 0996</phone>
    <email>praphan.p@chula.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Duanghathai Suttichom, BNS</last_name>
    <phone>66 2 254 2566</phone>
    <phone_ext>109</phone_ext>
    <email>duanghathai.s@searchthailand.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duanghathai Suttichom, BNS</last_name>
      <phone>66 2 254 2566</phone>
      <phone_ext>109</phone_ext>
      <email>duanghathai.s@searchthailand.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South East Asia Research Collaboration with Hawaii</investigator_affiliation>
    <investigator_full_name>Prof.Praphan Phanuphak, MD, PhD</investigator_full_name>
    <investigator_title>Director, the Thai Red Cross AIDS Research Centre</investigator_title>
  </responsible_party>
  <keyword>Acute HIV infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

